Triple Antiviral Therapy Promising for Mild-to-Moderate COVID-19

MONDAY, May 11, 2020 -- For patients with COVID-19, early triple antiviral therapy (lopinavir-ritonavir, ribavirin, and interferon beta-1b) is better than lopinavir-ritonavir for reducing the time to providing a nasopharyngeal swab negative for...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news